NEW YORK (GenomeWeb) – Precision medicine platform developer 2bPrecise and clinical genomics technology startup PierianDx have agreed to collaborate on a comprehensive tool for precision medicine decision-making at the point of care.
The companies said today that they would combine the knowledge base from PierianDx's Clinical Genomics WorkSpace platform with clinical information on cancer patients. 2bPrecise and PierianDx plan on integrating next-generation sequencing results with clinical information, then comparing that data with evidence-based content to create actionable care recommendations.
"We believe the power of precision medicine can best be achieved by combining a patient’s clinical data with genomic results at the point of care," Assaf Halevy, founder and CEO of 2bPrecise, a wholly owned subsidiary of electronic health records vendor Allscripts Healthcare Solutions, said in a statement.
"We anticipate that the synergies between our organizations will empower us to create a valuable solution offering that will enable a provider to utilize all of a patient’s clinical and genomic data to make treatment and clinical trial decisions," PierianDx CEO Michael Sanderson added.